Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Marco Fiorillo; Rebecca Lamb; Herbert B. B. Tanowitz; Anna Rita Rita Cappello; Ubaldo E. E. Martinez-Outschoorn; Federica Sotgia; Michael P. P. Lisanti

doi:doi:10.18632/aging.100983

← Back

Research Paper Volume 8, Issue 8 pp 1593—1606

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs)

Figure 2. Bedaquiline greatly diminishes oxygen consumption in MCF7 breast cancer cells. The Seahorse XF96 analyzer was employed to determine the mitochondrial function of MCF7 cells treated with bedaquiline (1μM and 10 μM) for 48 hours. (A) A line graph of 3 independent experiments is shown. (B, C, D) Respiration (basal and maximal), as well as ATP levels, were significantly decreased. *** p<0.0001, **** p<0.00001.